We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exoskeleton Use in Acute Rehab Post Spinal Cord Injury; a Safety and Feasibility Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03144830
Recruitment Status : Recruiting
First Posted : May 9, 2017
Last Update Posted : May 9, 2017
Sponsor:
Information provided by (Responsible Party):

April 20, 2016
May 9, 2017
May 9, 2017
June 2016
December 2017   (Final data collection date for primary outcome measure)
Change from baseline cardiorespiratory status throughout each of the 25 sessions [ Time Frame: Every 15 minutes during each training session including: pre and post initial stand, at 15 minute intervals during training and at the end of each of the 25 total sessions, on average of 2 months ]
Blood pressure, heart rate and peripheral oxygen saturation and will be used to identify any cardiovascular issues of orthostatic hypotension or autonomic dysreflexia.
Same as current
No Changes Posted
  • Skin integrity [ Time Frame: At the beginning and end of each training session for 25 sessions, on average of 2 months ]
    A visual inspection of areas of significant weight bearing and skin/machine interface will take place at the beginning and end of each training session to monitor for skin breakdown or compromise.
  • Falls [ Time Frame: From onset to cessation of each training session for 25 sessions, on average of 2 months ]
    Any incidence of falls will be recorded and the participant will be evaluated for injury by unit medical staff or on site emergency staff if warranted.
  • Pain visual analogue scale [ Time Frame: At the beginning and end of each training session for 25 sessions, on average of 2 months ]
    Participants draw an intersecting line on a 10 cm line (scale) in order to rate their amount of subjective pain. The distance on the 10 cm line is measured from the left side (no pain) and turned into a numerical value.
  • Borg scale of perceived exertion [ Time Frame: At the beginning, mid point (30 min) and end (60 min) of each training session for 25 sessions, on average of 2 months ]
    Subjects are shown the Borg scale of perceived exertion and are asked to choose the number/descriptor that best aligns with their current level of exertion at 0, 30 and 60 minutes.
  • 10 meter walk test [ Time Frame: Training sessions 1, 13 and 25 out of the 25 total sessions, on average of 2 months ]
    Time in seconds it takes a subject to walk a distance of 10 meters.
  • 6 minute walk test [ Time Frame: Training sessions 1, 13 and 25 of the 25 total sessions, on average of 2 months ]
    Total distance a participant is able to walk in 6 minutes will be measured.
Same as current
Not Provided
Not Provided
 
Exoskeleton Use in Acute Rehab Post Spinal Cord Injury; a Safety and Feasibility Study
Exoskeleton Use in Acute Rehab Post Spinal Cord Injury; a Safety and Feasibility Study
This study will examine the safety and feasibility of using an exoskeleton in subjects who are less than 6 months post spinal cord injury (SCI).

Study participants with acute SCI (<6 months post injury) will be involved in an indoor, overground walking program.

Locomotor training will include 90 minute sessions (including time to don and doff the device) for 30 training hours (90 minutes, 2-3 times weekly for 8 weeks.)

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Spinal Cord Injuries
Device: Exoskeleton
This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
Other Name: Ekso GT
Experimental: Overground walking program
Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
Intervention: Device: Exoskeleton
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
December 2017
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Individuals aged 15 and older with acute SCI (<6 months post) Etiology of SCI can be traumatic or non traumatic Includes motor complete (AIS A,B) and motor incomplete (AIS C,D) at C7 or below.

Participants must be able to follow 2 step commands Participants must be deemed medically stable by responsible physician or physiatrist

  • Spine considered stable by surgeon
  • Surgical wound is approximated and surrounding tissue appears healthy
  • Participant does not require supplemental Oxygen
  • Participant is able to have any IV or other lines disconnected.

Must meet manufacturer's requirements for use of Ekso GT:

Exclusion Criteria:

  • Range of motion (ROM) restrictions that would prevent a patient from achieving a normal, reciprocal gait pattern, or would restrict a patient from completing normal sit-to-stand or stand-to-sit transitions Spinal instability Untreated deep vein thrombosis (DVT) Decreased standing tolerance due to orthostatic hypotension Significant osteoporosis that prevents safe standing or may increase the risk of fracture caused by standing or walking Uncontrolled spasticity - score of 3 or higher on modified Ashworth Scale Uncontrolled Autonomic Dysreflexia (AD) Skin integrity issues on contact surfaces of the device or on surfaces that would prohibit sitting (sacrum, greater trochanter, proximal tibia)

Upper leg length discrepancy greater than half an inch (> .5") or lower leg discrepancy greater than three-quarters of an inch (>.75") Cognitive impairments resulting in motor planning or impulsivity concerns Pregnancy

Sexes Eligible for Study: All
15 Years and older   (Child, Adult, Senior)
No
Contact: Chester Ho, MD (403) 944 2061 chester.ho@ahs.ca
Contact: Kyle McIntosh, MScPT (403) 944 5358 kyle.mcintosh@ahs.ca
Canada
 
 
NCT03144830
EKSO22214
No
Not Provided
Plan to Share IPD: No
Chester Ho, MD, University of Calgary
University of Calgary
Not Provided
Principal Investigator: Chester Ho, MD University of Calgary
University of Calgary
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP